Meeting
2014 Genitourinary Cancers Symposium
Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists’ (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC).
Authors
Charles J. Ryan
University of California, San Francisco, San Francisco, CA
Charles J. Ryan , Mark R. Green , Susan L. Britton , Arden Buettner , Maria Lankford , Douglas Neely
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 492)
DOI
10.1200/jco.2014.32.4_suppl.492
Abstract #
492
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah
Poster
2014 ASCO Quality Care Symposium
Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.
First Author: Lori Wood
Poster
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
First Author: Lothar Mueller